AC Immune Update on Phase 2 Immunotherapy Pipeline for Alzheimer's, Parkinson's

 

• ABATE Phase 1b/2 AD trial of ACI-24.060 completed enrollment of cohorts 1 and 2 and is expected to complete cohort 3 in January; 6-month and 12-month amyloid PET data expected in H1 & H2 2024, respectively
• ReTain Phase 2b clinical trial of ACI-35.030 in preclinical AD being launched now by partner

• VacSYn Phase 2 PD trial of ACI-7104.056 completed enrollment of cohort 1 and commenced cohort 2; safety and immunogenicity update expected in H2 2024
• Cash for operations extends into 2026 with USD50 million equity financing and ACI-35.030-related milestones

https://www.globenewswire.com/news-release/2024/01/03/2803284/0/en/AC-Immune-Progress-Update-on-Phase-2-Active-Immunotherapy-Clinical-Pipeline-for-Alzheimer-s-and-Parkinson-diseases.html